• Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page

ANOTHER HIT FOR NUBU

Quote
getting Optum is good, but if you look at the letter we are to send, they say do not make it clear at all that they can't get Emgality at all, and they put Aimovig and Ajovy in there. Everyone will just switch from Emgality to Ajovy as we are making it clear as day they can use both. Why did they HAVE to put both down? They didn't. The competitors did NOT when we lost CVS. Another Amgen mess.

I don't think it's going to help much at all
 




Nope I don't think this will help. The letter makes it look as if Ajovy is also preferred and gives them free reign to use other products. It's not worded well at all. Emgality's push against us with CVS was far stronger as was Ajovy's. We as usual are the pu##ws@@sys.
 












anonymous said:
You are SO right. Hire more people? Whose freaking idea was THAT? Really smart Amgen!!!

We are ready to fold!!!
Click to expand...

Now we will contend with Pfizer, great! I know for a fact that in 2018 - 2019, VP Dave Marek and Ross Arno were in BD meetings pushing Amgen to buy Biohaven in the range of 2.5 - 3 billion, what a deal! Can you imagine having a full portfolio now? Apparently Ross went apeshit when the Novartis-Amgen leaders emphatically said "orals will never be more than 4% of the market". I'm not saying the deal would have gone through, the collaboration may have stopped that, but the mere leadership arrogance and lack of pipeline awareness is shocking. Pfizer will take our business, customers, and eat our lunch.
 




anonymous said:
Now we will contend with Pfizer, great! I know for a fact that in 2018 - 2019, VP Dave Marek and Ross Arno were in BD meetings pushing Amgen to buy Biohaven in the range of 2.5 - 3 billion, what a deal! Can you imagine having a full portfolio now? Apparently Ross went apeshit when the Novartis-Amgen leaders emphatically said "orals will never be more than 4% of the market". I'm not saying the deal would have gone through, the collaboration may have stopped that, but the mere leadership arrogance and lack of pipeline awareness is shocking. Pfizer will take our business, customers, and eat our lunch.
Click to expand...


exactly amgen is so arrogant. they should have bought it. the optum win is nothing like losing cvs and having no bridge doesn't help.
 




anonymous said:
Now we will contend with Pfizer, great! I know for a fact that in 2018 - 2019, VP Dave Marek and Ross Arno were in BD meetings pushing Amgen to buy Biohaven in the range of 2.5 - 3 billion, what a deal! Can you imagine having a full portfolio now? Apparently Ross went apeshit when the Novartis-Amgen leaders emphatically said "orals will never be more than 4% of the market". I'm not saying the deal would have gone through, the collaboration may have stopped that, but the mere leadership arrogance and lack of pipeline awareness is shocking. Pfizer will take our business, customers, and eat our lunch.
Click to expand...


ROSS was right. Orals are FAR more than 4% of the CGRP market. They are eating all injectable CGRP's lunch.
 




anonymous said:
exactly amgen is so arrogant. they should have bought it. the optum win is nothing like losing cvs and having no bridge doesn't help.
Click to expand...

Guaranteed he'll bail to a pre-ipo biotech this year, bank on it. He's too fast paced and believes we should follow the McKinsey 7s model. The dude hates endless red tape and redundancy. He should have known better, Amgen is big pharma on steroids.
 




Hard to explain how fake a show it is unless you work in it. Gone are the days you can suggest new things instead you tow the line for TN. Meanwhile, TN protects her incompetent Director KD.
 




















anonymous said:
getting Optum is good, but if you look at the letter we are to send, they say do not make it clear at all that they can't get Emgality at all, and they put Aimovig and Ajovy in there. Everyone will just switch from Emgality to Ajovy as we are making it clear as day they can use both. Why did they HAVE to put both down? They didn't. The competitors did NOT when we lost CVS. Another Amgen mess.

I don't think it's going to help much at all
Click to expand...

the Optum is nothing as compared to CVS. KD thinks Optum is going to save the nubu diviision
 








anonymous said:
no. can't even use ajovy until July 1. it's not preferred
Click to expand...


IT's irrelevant. July is fast approaching. They are getting the letters and it clearly states they can also use Ajovy. They'll move from one ligand blocker to another. Ajovy will get the business

KD can dream on that this will save the day, but he's mistaken as usual
 




anonymous said:
exactly amgen is so arrogant. they should have bought it. the optum win is nothing like losing cvs and having no bridge doesn't help.
Click to expand...

agree

I've spoken to quite a few offices, and Optum is not a big player. Some don't even take Optum. CVS is #1.

KD and the others can continue their nonsense, but it's not going to help. GET CVS BACK
 












anonymous said:
FAT CHANCE

half the country making bonus and 1/4 making little and 1/4 making nada

nubu going down

tiffany does not care about the field
Click to expand...

Lookie here, most hq people have left with more on their way out. The model of hiring and bringing friends from the field to hq roles is and was a bad idea. Hiring who you know vs. who can do the job is bad news. Doing this causes a potpourri of problems ranging from ic, managed care, resources, and customer sentiment. Soooo, how do we fix things?
 




Top Bottom
Back
Quote